Following on from the recent first global approval[1] of midostaurin in the US, in December 2017, midostaurin (Rydapt™), developed by Novartis Pharmaceuticals, was also approved in Canada for FLT3 mutated acute myeloid leukemia (AML).[2]

Dr. Aaron Schimmer, medical oncologist and senior scientist, Princess Margaret Cancer Centre, University Health Network and investigator for the RATIFY trial, said that, “AML is a very serious and life-threatening condition, and this is the first time in a long time that we’ve seen an advance in this area and it’s encouraging for me as a treating physician.” [2]

Further details are available in the First Global Approval report in Adis’ journal Drugs[3], these are based on the development milestones tracked in AdisInsight.[4]

Image credit:  Ivelin Radkov / Fotolia

Leave a Reply